Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophageal Carcinoma | Phase 1 | China | 01 Feb 2016 | |
| Gallbladder Carcinoma | Phase 1 | China | 01 Feb 2016 | |
| HER2-Positive Digestive System Neoplasms | Phase 1 | China | 01 Feb 2016 | |
| Intestinal Neoplasms | Phase 1 | China | 01 Feb 2016 | |
| Liver Cancer | Phase 1 | China | 01 Feb 2016 | |
| Pancreatic Cancer | Phase 1 | China | 01 Feb 2016 | |
| Stomach Cancer | Phase 1 | China | 01 Feb 2016 |






